Want to invest with us?Investor PortalJLS logo

JLS Fund: Investments at the Intersection of Psychedelics & Technology

JLS was formed to invest in the exciting intersection of science, technology and neurology, leveraging the enormous potential of plant-based and psychedelic medicines to heal illness and enhance wellness. We focus on the development of drugs for intractable mental and physical conditions and the enabling technology and tools that can accelerate and enhance the delivery of those therapies.

arrow

Investments & Advisories

Investments

Parow logo

Parow

Fully integrated, pre-clinical stage biotechnology company developing therapeutics for the accessible treatment of psychiatric diseases

Firefly VR logo

Firefly VR

Immersive virtual environments that improve the treatment of mental health

Lief Therapeutics Logo

LIEf Therapeutics

An intelligent, clinically accurate HRV wearable device for mental health

Mindmed

MindMed discovers and develops psychedelics inspired medicines

Mindmed logo
Gilgamesh logo

Gilgamesh

Gilgamesh is developing the next generation of central nervous system drugs derived from psychedelics

Diamond Therapeutics Logo

Diamond therapEutics

Diamond Therapeutics develops psilocybin based medicines while mitigating side effects

Myco Systemics Logo

Myco systemics

Myco Systemics' mission is to provide systemic scalable myco-cultivation infrastructure to enable producers to meet the demands of the exploding global mushroom market

Tactogen Logo

Tactogen

Tactogen is a public benefit cooperation whose goal is to make transformative medicines safer, more effective, and more accessible

Mindleap Health logo

MINDLEAP HEALTH

Mindleap's integration coaches help you to understand and embody the most important parts of your Psychedelic trip, allowing you to create lasting personal transformation.

Atai Life Sciences Logo

atai life sciences

ATAI is committed to developing more effective and potentially disease-modifying mental health treatments by researching both psychedelic and non-psychedelic compounds.

Universal Ibogaine logo

universal ibogaine

Universal Ibogaine's mission is to bring proven Ibogaine based clinical treatment protocol to the world and help solve the international opioid crisis

Good Cap Logo

GoodCap

GoodCap is developing effective mushroom-based treatments that open new pathways to a healthier future.

Gwella logo

GWELLA

Gwella's focus is on developing transformative consumer brands, products and technologies aimed at elevating people's health and wellbeing.

Lucid News logo

LUCID NEWS

Lucid News provides informed, honest and transparent journalism that covers the growing integration of psychedelics into society and their broad implications for human wellness.

orthogonal

Orthogonal's mission is to give people access to nature’s most effective health solutions while setting the standard of a new “Farma”: Food as Medicine.

Double Blind logo

double blind

.

A digital media company covering psychedelics and all they intersect with, from healthcare disparities to the climate crisis

Wesana logo

wESANA

.

A life sciences company whose mission is to treat traumatic brain injury and other mental health ailments using psilocybin and other natural therapies.

Maya health logo

MAYA HEALTH

Psychedelic Therapy Software & Management.

Awakn life sciences logo

AWAKN LIFE SCIENCES

Awakn Life Sciences is a biotechnology company with clinical operations researching, developing, and delivering psychedelic new chemical entity drugs and therapies to treat Addiction.

Tripp logo

TRIPP

TRIPP is an award-winning breakthrough wellness platform.

Psilera Bioscience logo

Psilera Bioscience

Psilera is reimagining psychoactive natural products as building blocks for the next generation of neurological therapeutics.

Meet the team

Lindsay Hoover
LinkedIn
LINDSAY HOOVER
Managing partner
jefferey siegel
LinkedIn
JEFFREY SIEGEL
Partner & Investor Relations
simeon schanpper
LinkedIn
SIMEON SCHNAPPER
Managing partner
Michael Gruber headshot
LinkedIn
Michael Gruber
Managing Partner
walter greenleaf
LinkedIn
WALTER GREENLEAF
Advisor
David Hirsch
LinkedIn
David Hirsch
Advisor
Ethan Nadelmann
LinkedIn
Ethan Nadelmann
Advisor
Pickard Headshot
LinkedIn
Leonard Pickard
Advisor

Upcoming Events

Keep your eye on this space for information on upcoming panel discussions, speaking engagements, conferences and more featuring members of the JLS team and our extended community.

Press

forbes logo

BENZINGA

Simeon Schnapper is among the major psychedelics VC & EFT directors who shared valuable insights at the Psychedelics Capital Conference (PCC)

forbes logo

Business Insider

JLS named one of the top VCs that's turning psychedelics into medical treatments

forbes logo

Business Insider

Gilgamesh was named one of the "15 hottest startups in the psychedelics industry"

forbes logo

LUCID News

How Awkn is navigating the tough market for investment capital

LUCID News

Psychedelics were the hot topic at the World Economic Forum 2022

forbes logo

LUCID News

How Awkn is navigating the tough market for investment capital

LUCID News

How Awkn is navigating the tough market for investment capital

forbes logo

Benzinga

Can Psychedelics Therapy Training Become A Profitable Business? We Asked Industry Insiders

forbes logo

Business insider

Investors share why they're passing on Oregon's magic mushroom market

forbes logo

Toronto Star

He was the Canadian head of the world’s largest pot company. His next big bet? A rare fungus worth thousands a kilogram

forbes logo

Benzinga

Will Psychedelics Continue To Grow In 2021? Jeff Siegel Shares Insights And Strategies As More Companies Go Public

forbes logo

Benzinga

Why Would Anyone Invest In The Psychedelics Medicine Market?

Psychedelic Alpha logo

psychedelic alpha

Interview with Simeon Schnapper, Managing Partner of JLS

forbes logo

Forbes

Why Investors Are Bullish About Psychedelics

forbes logo

Psychedelic Finance

Interview with Jeff Siegel, Managing Partner of JLS Fund

Terpenes and Testing

terpenes and testing

Ibogaine: The ‘Strange Kind of Drug’ for Transcending Addiction

Bloomberg

Bloomberg

Psychedelics Replace Pot as the New Favorite Edgy Investment

forbes logo

Benzinga

Why The Psychedelics Market Is NOT Cannabis 2.0

Business Insider

business insider

Investors are pouring millions into startups that are developing magic mushrooms as medications for conditions like depression and PTSD

Business Insider

Business Insider

Meet the top 14 psychedelics startups raising the most cash to develop new ways of treating depression, addiction, and more

Green Market Report

green market report

Psychedelic Industry Continues To Draw Millions In Investments

Speaking & Panel Appearances

Investments

forbes logo

THE PSYCHEDELIC
ASSEMBLY

Simeon Schnapper co-hosted a thought provoking discussion on the intersection of psychedelics, AI, and robotics.

forbes logo

BEnzinga

Simeon Schnapper spoke at the Benzinga Psychedelics Capital Conference in Miami Beach, Florida.

forbes logo

Boston Psychedelic Research Group

William Leonard Pickard spoke at a private event

Boston Psychedelic Research Group

William Leonard Pickard spoke at a private event

Boston Psychedelic Research Group

William Leonard Pickard spoke at a private event

forbes logo

PsychedeMIA

William Leonard Pickard spoke at an interdisciplinary symposium at Ohio State University on the future of psychedelic research

forbes logo

Wholecelium

William Leonard Pickard spoke at the first annual "Psychedelic Science and Spirituality Summit" in Stowe, Vermont

forbes logo

Horizons Northwest

William Leonard Pickard spoke at Horizons Northwest's "Perspectives on Psychedelics" conference

forbes logo

REMIND psychedelics Business Forum

Simeon Schnapper spoke on the "Investing in Psychedelics" panel

forbes logo

Wonderland Microdose Miami 2022

Lindsay Hoover and Simeon Schnapper both spoke on respective panels

forbes logo

Horizons

Lindsay Hoover spoke at Horizons: The Psychedelic Business Forum, the largest and longest-running annual gathering of the psychedelic community in the world

forbes logo

AGC New York

Simeon Schnapper spoke at the ACG New York Family Officer & Limited Partner Series.

forbes logo

ICPR 2022

Simeon Schnapper spoke on a panel discussing the intersection of psychedelic research, treatments, and investment

forbes logo

PSYCHOACTIVE

Simeon Schnapper on the tensions between philanthropic and for-profit investment, and the challenges and opportunities of this explosive new sector.

forbes logo

the psychedelic assembly

Lindsay Hoover and Senior Advisor to JLS Fund, Leonard Pickard

forbes logo

European Ibogaine Forum

Political Importance of Ibogaine Development with Rick Doblin, JLS' Simeon Schnapper, and Daniel Callahan

forbes logo

Alchemy

Simeon Schnapper and Lindsay Hoover discuss investing in the psychedelic space and the developing ecosystem of this emerging industry.

forbes logo

Women in Psychedelics Network

With Lindsay Hoover

forbes logo

Trailblazers NYC

Revealing the Mind: The Promise & Opportunity of Psychedelics with Simeon Schnapper

forbes logo

Wonderland  Miami

Lindsay Hoover presented at a panel entitled: Psychedelic Capital Live

forbes logo

Wonderland  Miami

William Leonard Pickard presented at a panel entitled: The Pathway to Federal Acceptance

forbes logo

Wonderland  Miami

JLS advisor Ethan Nadelaman spoke on the "Pathway to Federal Acceptance" panel

forbes logo

psychedelics today

Lindsay Hoover speaks on Consolidation in the Psychedelics Industry: What to Expect

forbes logo

Cato Institute

William Leonard Pickard and Caleb O. Brown discuss promise and pitfalls in taking psychedelic medicine mainstream.

forbes logo

Benzinga psychedelics capital conference

Lindsay Hoover on differentiating opportunities between private & public companies

forbes logo

REAL VISION

Jeff Siegel on investing in the future of mental healthcare: psychedelics as an asset class

forbes logo

Trailblazers Ojai

Revolutionizing Healing Through Psychedelic Medicine with Simeon Schnapper

Singularity University

Singularity U

Simeon Schnapper in Singularity U's first ever panel on psychedelics!

The Psychedelics Society

The Psychedelics Society

Psychedelics Roundtable with Simeon Schnapper of JLS Fund

Gravity Podcast

Gravity Podcast

Psychedelic Philanthropy with Simeon Schnapper of JLS Fund

Small Cap Conference

Benzinga Small Cap Conference

Simeon Schnapper moderates a panel on addressing mental health through emerging therapies.

Gravity Podcast

Gravity Podcast

Simeon Schnapper of JLS Fund

2021 Games for Change Festival July 12-14

Games for Change Festival

Lindsay Hoover of JLS Fund: Psychedelics as Therapeutics: The Contribution of Game Heuristics

Where Research and Industry Meet: Psytech Panel

Psytech “Where Research and Industry Meet”

Lindsay Hoover of JLS Fund

The Green Rush

the green rush

Lindsay Hoover and Simeon Schnapper, Managing Partners of JLS Fund

Mindmed

Mindmed

Understanding The Psychedelic Medicine Industry: Q&A with Kevin O'Leary and JR Rahn

Psyched

Psyched

Watch Simeon Schnapper on Pysched, the show that explores psychedelics through political, social, and economic perspectives.

Moderated Conferences

INAUGURAL MICRODOSE CONFERENCE

Moderated by Simeon Schnapper

CEO Panel #1: Srinivas Rao MD, PhD- (ATAI) Payton Nyquvest (Numinus), Judy Blumstock (Diamond Therapeutics) Shlomi Raz (Eleusis), Ronan Levy (FieldTrip)

CEO Panel #2: Jackee Stang (Delic), Todd Shapiro (Red Light Holland), Jonathan Sporn MD (Gilgamesh), Martijn Schirp (Synthesis)

The Mushroom: Paul Stamets (Simeon’s hero), Gary Costner (Mycosystemics), David Kurth (Sporing Company), Eric Osborne (MycoMeditations), Dr K Mandrake (Psilocybin Mushroom Bible)

Venture Capital & Funding: Robert Laurie (MAPS), Florian Brand (ATAI), Mark Hazan (Tabula Rasa) Matthew Nordgren (Arcadian Fund), Bek Muslimov (Leafly Tunnel), Richard Skaife (TCF VC)

Watch
Microdose

Know Thyself: Psychedelics & Spirituality

Moderated by Simeon Schnapper

• The State and Future of Psychedelic Therapist Training with Elizabeth M. Nielson, PhD
• MDMA and Transformative Psychedelic Therapy with Dr. Rick Doblin
• MDMA-assisted Psychotherapy: Beyond Symptom Reduction with Dr. Ingmar Gorman
• Healing What Divides Within with Dr. Willa Hall
• PANEL Q&A: MDMA Therapy with Dr. Hall & Dr. Gorman
• MDMA-Assisted Psychotherapy & Social Anxiety Disorder with Dr. Jason Luoma
• MDMA for Couples Therapy Love & Connection Love and connection with Dr. Anne Wagner
• PANEL Q&A: MDMA Therapy with Dr. Luoma & Dr. Wagner
• The Future of MDMA-Assisted Therapy & Availability Dr. Corine de Boer
• Use of Natural Mind-Altering Substances: Cannabis with Dr. Darryl Hudson
• Psychedelics and Depression with Dr. Xiaojue Hu

All proceeds benefit the Tibet House.

Watch
Tibet House logo

Benzinga

Moderator: Simeon Schnapper

Addressing Mental Health Through Emerging Therapies" Panel

Panelists: Dr. Joseph Tucker, CEO, Enveric; Yaron Conforti, CEO, Novamind; Doug Drysdale, CEO, Cybin; Rob Barrow, CEO, MindMed

Watch
Benzinga Logo

The National Cannabis Festival

Moderator: Simeon Schnapper

Psychedelics: The Next Frontier for Legalization

Panelists: Mellisa Lavasani, Founder of Plant Medicine Coalition and Proposer of Washington DC’s successful 2020 ballot measure Initiative 81, the Entheogenic Plant and Fungus Policy Act.

National Cannabis Festival

Trailblazers: Sedona

May 2022

- Fireside Chat with Simeon Schnapper and Leonard Pickard
- The Investor State of Mind - WTF is happening?- with Michael Gruber
- Invest In The Future Of Medicine - The Psychedelic Investment Opportunity- with Lindsay Hoover

RECAP
Trail Blazers

Capital Psychedelic Conference

June 7, 2022

- JLS moderated a panel on alternative medicine and harm reduction featuring government officials and industry experts.

Capital Psychedelic Coalition Event

Trailblazers NYC 2022

Moderated by Simeon Schnapper

Revealing The Mind: The Promise + Opportunity of Psychedelics

Panelists: Simeon Schnapper, Sutton King, Hadas Alterman, Liana Gillooly

Recap
Trailblazers Tribeca

Investor Reports

Weekly Updates

Stay up to speed with the world of psychedelics with our weekly updates. Sign up.

Contact

Ready to invest? See if you qualify.

Take Our Qualification Survey

Is your company in the psytech space?

Company Inquiry Form

Have questions or want to learn more?

General Inquiries